BriaCell Therapeutics (TSE:BCT) has released an update.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
BriaCell Therapeutics has received approval from the Data Safety Monitoring Board to continue its Phase 3 study of a novel immunotherapy for metastatic breast cancer, a promising development under FDA Fast Track Designation. The study’s continuation without protocol modifications marks a significant step forward for the company’s innovative cancer treatment.
For further insights into TSE:BCT stock, check out TipRanks’ Stock Analysis page.
